





Please type a plus sign (+) inside this box → ☐

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/088 (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

### Complete if Known

Application Number	09/807,332
Filing Date	April 11, 2001
First Named Inventor	Thomas G. Burke
Group Art Unit	
Examiner Name	
Attorney Docket Number	434-204

CH CENTER 1600/2900

SEP 24 2001

RECEIVED

### OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	1	JAXEL et al., Effect of Local DNA sequence on Topoisomerase I Cleavage in the Presence or Absence of Camptothecin. The Journal of Biological Chemistry. 25 October 1991, Vol. 266, No. 30, pages 20418-20423, especially the abstract.	
	2	Database Caplus on STN, AN 1997:725569, FLEURY et al. Conformation and mechanism in DNA-topoisomerase I as a target of antitumor drugs: optical spectroscopy approach. Spectrosc. Biol. Mol. Mod. Trends. 1997, Eur. Conf. 7th, Conference Abstrct.	
	3	LETEURTRE et al. Specific Interaction of Camptothecin, a Topoisomerase I Inhibitor, with Guanine Residues of DNA detected by Photoactivation at 365 nm. Biochemistry. 1993, Vol. 32, pages 8955-8962, especially abstract.	
	4	GIOVANELLA, et al., DNA Topoisomerase I-Targeted Chemotherapy of Human Colon Cancer in Xenografts, Science 246: 1046-1048 (Washington, DC) (1989)	
	5	MADDEN, T.D., BURKE, T.G., REDELMEIER, T.E. and BALLY, M.B., "Encapsulation of Topotecan in Lipid-Based Carriers: Evaluation of Drug Stability and Plasma Elimination in a Murine Model", Proc. Am. Soc. Clin. Oncol., 17: 196a (1998)	

Examiner Signature		Date Considered	2/12/02
--------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.